<DOC>
	<DOC>NCT01192945</DOC>
	<brief_summary>The purpose of this non-interventional study is to collect data on the efficiency and safety of Azacitidin in the routine application.</brief_summary>
	<brief_title>Non-interventional Study With Azacitidin (Vidaza®)</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients who are not eligible for haematopoietic stem cell transplantation, who are at least 18 years old (no age limit to top) and who have one of the following diseases: myelodysplastic syndrome (MDS) with intermediate risk 2 or high risk according to the International Prognostic Scoring System (IPSS) chronic myelomonocytic leukemia (CMML) with 1029% marrow blasts without myeloproliferative disorder acute myeloid leukemia (AML) with 2030% blasts and multilineage dysplasia according to classification of the World Health Organisation (WHO). Contraindication according to the summary of product characteristics of Vidaza® Signed patient informed consent form is not available Patients with advanced malignant hepatic tumors Pregnant or nursing women, men and women (of childbearing age) who are unwilling to apply a reliable method of contraception during and up to three months after treatment with Azacitidine Necessary or planned treatment with other systemic cytostatics Known medical history of severe decompensatoric cardiac insufficiency Medical history of clinically unstable cardiac or pulmonary disease Known or suspected hypersensitivity to azacitidine or mannitol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Azacitidin</keyword>
	<keyword>Vidaza</keyword>
	<keyword>Piaza</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>CMML</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>daily routine</keyword>
	<keyword>concomitant antiemetic therapy</keyword>
	<keyword>germany</keyword>
	<keyword>non-interventional study</keyword>
</DOC>